Riluzole Attenuates L-DOPA-Induced Abnormal Involuntary Movements Through Decreasing CREB1 Activity: Insights from a Rat Model

Chronic administration of L-DOPA, the first-line treatment of dystonic symptoms in childhood or in Parkinson’s disease, often leads to the development of abnormal involuntary movements (AIMs), which represent an important clinical problem. Although it is known that Riluzole attenuates L-DOPA-induced...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Neurobiol
Main Authors: Pagliaroli, Luca, Widomska, Joanna, Nespoli, Ester, Hildebrandt, Tobias, Barta, Csaba, Glennon, Jeffrey, Hengerer, Bastian, Poelmans, Geert
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2018
Assuntos:
Original Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6647536/
https://ncbi.nlm.nih.gov/pubmed/30484112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12035-018-1433-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados